3.915  -0.065 (-1.63%)		12-12 15:59
Open: 4 High: 4.03 Volume: 45,202		Pre. Close: 3.98 Low: 3.915 Market Cap: 40(M)

Short term
Mid term
Targets	6-month :	4.75	1-year :	5.55
Resists	First :	4.07	Second :	4.75
Pivot price	3.86
Supports	First :	3.71	Second :	3.5
MAs	MA(5) :	3.97	MA(20) :	3.8
	MA(100) :	3.53	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	81.5	D(3) :	84.3
RSI	RSI(14): 57.5
52-week	High :	4.07	Low :	2.29

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PYPD ] has closed below upper band by 41.4%. Bollinger Bands are 19% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.03 - 4.06	4.06 - 4.08
Low:	3.86 - 3.89	3.89 - 3.91
Close:	3.87 - 3.92	3.92 - 3.95

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Wed, 10 Dec 2025
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets

Wed, 03 Dec 2025
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets

Wed, 03 Dec 2025
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire

Tue, 25 Nov 2025
PolyPid Ltd. to Host Virtual KOL Event on D-PLEX100 and Surgical Site Infection Prevention - Quiver Quantitative

Tue, 25 Nov 2025
PolyPid (Nasdaq: PYPD) to Join ROTH Capital KOL Webinar on D-PLEX100 Surgical Infections - Stock Titan

Thu, 13 Nov 2025
PolyPid Ltd. (NASDAQ:PYPD) Q3 2025 Earnings Call Transcript - Insider Monkey

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	17 (M)
Shares Float	10 (M)
Held by Insiders	15.7 (%)
Held by Institutions	38.4 (%)
Shares Short	58 (K)
Shares Short P.Month	58 (K)

EPS	-2.81
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.92
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-88 %
Return on Equity (ttm)	-390.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.88
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-1.4
PEG Ratio	0
Price to Book value	4.25
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.